Characteristics and Results of Patients Treated by Therapeutic Intensification

NCT06894381 | Recruiting

• 1 other identifier: 9061
• Study Type: observational
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

Many studies have focused on patients treated with allogeneic peripheral stem cell transplantation; few studies have until now been carried out to describe the characteristics and results of autografted patients and to attempt to determine possible prognostic factors. However, it is estimated that nearly 5% of autograft patients require MIR care. The investigators therefore wish to conduct a retrospective study including patients treated by therapeutic intensification followed by autograft of hematopoietic stem cells and admitted to the MIR department of the Hautepierre hospital of the University Hospitals of Strasbourg (HUS) within thirty days following initiation of chemotherapy.

Conditions

Malignant Hemopathy

Keywords

Malignant hemopathy; allogeneic; stem cell; transplantation; chemotherapy

Outcome Measures

Primary Outcomes (1)

• Retrospective description of the clinical and biological characteristics of patients having therapeutic intensification and autograft of peripheral stem cells for the treatment of hematological malignancy

  Thirty days following therapeutic intensification and autograft of peripheral stem cells in treatment of a malignant hematological disease.

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult patient (≥18 years old) admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy

You may qualify if:

• Adult patient (≥18 years old)
• Gender indifferent
• Admitted to the Intensive Care Unit within thirty days following therapeutic intensification and autograft of peripheral stem cells for the treatment of a hematologic malignancy between 01/01/2013 and 12/31/2022

You may not qualify if:

• \- Subject having expressed his opposition to the reuse of his data for scientific research purposes

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service de Médecine Intensive - Réanimation - CHU de Strasbourg - France

Strasbourg, 67091, France

RECRUITING

Central Study Contacts

Vincent CASTELAIN, MD, PhD

CONTACT

33.3.88.12.79.15; vincent.castelain@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 4, 2024
• First Posted: March 25, 2025
• Study Start: January 20, 2024
• Primary Completion: December 1, 2025
• Study Completion: December 20, 2025
• Last Updated: March 25, 2025

Record last verified: 2024-04

Locations

FR (1)